复发性子宫内膜癌的非脏器切除性手术治疗
本研究回顾性分析了376例原发性子宫内膜癌术后复发患者,比较非脏器切除性二次减瘤手术(SCS)与非手术治疗的效果。结果显示,接受SCS的61例患者(16.2%)总生存期最长(57.6个月,95%CI 33.3-未达到),多因素分析中SCS是改善生存的独立预测因素。结论认为在医学上适合的患者中应尽可能考虑手术治疗,并注意患者选择。
要点
- 复发性子宫内膜癌患者中,接受二次减瘤手术者总生存期最长,达57.6个月。
- 多因素分析显示二次减瘤手术是改善生存的独立预测因素。
- 手术患者多较年轻、子宫内膜样组织学、初诊I期、初次手术后无残留病灶。
核心结论
- 在复发性子宫内膜癌患者中,接受非脏器切除性二次减瘤手术者即使控制肿瘤大小、部位、组织学、分期和复发时间后仍显示最大生存获益。
研究设计与样本
- 回顾性队列研究,纳入2009年1月1日至2017年12月31日期间接受原发性手术治疗的子宫内膜癌后复发患者,共376例。
主要发现
- 376例复发患者中,61例(16.2%)接受二次减瘤手术,257例(68.4%)接受药物管理(化疗和/或放疗),32例(8.5%)接受激素治疗,26例(6.9%)未接受进一步治疗。
- 二次减瘤手术组总生存期最长,为57.6个月(95%CI 33.3-未达到)。
- 多因素分析中二次减瘤手术是改善生存的独立预测因素。
- 在61例手术患者中,单因素分析显示初诊时年龄<70岁和组织学为子宫内膜样与复发后生存改善相关(p值分别为0.008和0.03)。
临床怎么用
- 在医学上适合的复发性子宫内膜癌患者中,应尽可能考虑手术治疗。
- 患者选择需谨慎,有利的肿瘤因素可能对改善结局起重要作用。
局限性
- 本研究为回顾性研究,手术患者存在选择偏倚,可能影响结果解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the role of non-exenterative secondary cytoreductive surgery (SCS) compared with non-surgical treatments and identify predictors of improved survival for patients with recurrent endometrial cancer (EC). METHODS: All patients undergoing primary surgical management for EC 1/1/2009-12/31/2017 who subsequently developed recurrence were retrospectively identified. Survival was determined from date of diagnosis of first recurrence to last follow-up and estimated using Kaplan-Meier method. Differences in survival were analyzed using Log-rank and Wald tests, based on Cox Proportional Hazards model. RESULTS: Among 376 patients with recurrent EC, median time to recurrence was 14.3 months (range, 0.2-102.2), post-recurrence median survival 29 months, median follow-up 29.2 months (range, 0-116). Sixty-one patients (16.2%) received SCS, 257 (68.4%) medical management (MM) (chemotherapy and/or radiation therapy), 32 (8.5%) hormonal therapy, 26 (6.9%) no further therapy. Patients selected for SCS were younger, had more endometrioid histology, more stage I disease at initial diagnosis, no residual disease after primary surgery, longer interval to first recurrence or progression, and the longest OS (57.6 months) (95% CI, 33.3-not reached). On multivariate analysis SCS was an independent predictor of improved survival. Among the 61 SCS patients, age < 70 at time of initial diagnosis, and endometrioid histology, were associated with improved post-relapse survival univariately (p = 0.008, 0.03, respectively). CONCLUSIONS: While MM was the most common treatment for first recurrence of EC, patients selected for surgery demonstrated the greatest survival benefit even after controlling for tumor size, site, histology, stage, time to recurrence. Careful patient selection and favorable tumor factors likely play a major role in improved outcomes. Surgical management should be considered whenever feasible in medically eligible patients, with additional consideration given to our suggested criteria.
引用
- Moukarzel LA, Braxton KF, Zhou QC, et al. Non-exenterative surgical management of recurrent endometrial carcinoma. Gynecol Oncol. 2021. PMID: 34090704. doi:10.1016/j.ygyno.2021.05.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。